Physician profile
Colin Milo
NPI 1962195768
$1,637.51
in general payments reported to CMS, 2019-2025
10 companies · $560 in 2025
The $560 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $180 · 2024: $898 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,637.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $396.82 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Abbvie INC. | $317.77 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $315.38 | 2023-2025 | Miebo, Infuse, Xiidra |
| Johnson & Johnson Vision Care, INC. | $247.49 | 2024-2025 | Acuvue |
| Glaukos Corporation | $139.83 | 2024 | |
| Dompe US, INC. | $118.23 | 2024 | Oxervate |
| Alcon Vision LLC | $57.58 | 2023-2024 | Precision 1, Total30 |
| Amgen INC. | $16.73 | 2025 | Tepezza |
| Coopervision INC. | $14.04 | 2023 | Myday Contact Lens |
| Thea Pharma INC. | $13.64 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Milo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.